SITC Cancer Immunotherapy Guidelines – Immune Effector Cell-Related Adverse Events GuidelineOpen Comment Period – August 14 to September 11, 2020
The Society for Immunotherapy of Cancer (SITC) Immune Effector Cell-Related Adverse Events Guideline Expert Panel is pleased to invite public comment from August 14 – September 11, 2020 for the draft of the forthcoming, “The Society for Immunotherapy of Cancer consensus statement on immune effector cell-related adverse events” manuscript.
This clinical practice guideline is the first in SITC’s series of immunotherapy toxicity guidelines. A forthcoming clinical practice guideline, devoted to the recognition and management of immune checkpoint inhibitor-related adverse events, is currently in development.
SITC’s open public comment period allows for key stakeholders and other experts in the field – both within and outside of our membership – to critically review the guideline and provide input prior to publication. SITC is committed to maintaining full transparency in our guideline development process, in alignment with the Institute of Medicine’s standards, for the ultimate purpose of developing quality clinical practice guidelines to aid practitioners in providing the best possible care to their patients.
Instructions for participating in the open comment period are provided below. Prospective reviewers will be required to sign a non-disclosure and confidentiality agreement prior to obtaining the draft manuscript. All comments must be received by 11:59 pm PT, Friday, September 11, 2020, to be considered.
Instructions for Requesting Draft Manuscript
Download the non-disclosure and confidentiality agreement HERE
Email the completed document to email@example.com
A copy of the guideline will be sent within 1-2 business days after receipt of the complete form (anonymous comments will not be accepted)
Further instructions about how to provide comment will be included with the draft
All comments received during the open comment period will be reviewed by the Immune Effector Cell-Related Adverse Events Guideline Expert Panel leadership. Comments are advisory only and SITC is not obligated to make any suggested changes based on comments received. SITC will consider all submissions, but will not respond directly to individual commenters.SITC is a proponent for collaboration and harmonization of efforts between like-minded organizations whenever possible. SITC wishes to thank the American Society of Hematology (ASH), the American Society for Transplantation and Cellular Therapy (ASTCT) and the Foundation for the Accreditation of Cellular Therapy (FACT) at the University of Nebraska Medical Center for providing representatives to serve on SITC’s Immune Effector Cell-Related Adverse Events Expert Panel to aid in the development of this clinical practice guideline.
35th Anniversary Annual Meeting & Pre-Conference Programs
SITC Members: Register to Attend for Free!
Easily Become a SITC Member Through your SITC 2020 Registration
Share This Exciting Virtual Meeting Within Your Network:
CIG NDA ABOUT THE IEC-rAE EXPERT PANEL
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org